

1st ASEICA-MED RETREAT

SANTIAGO DE COMPOSTELA

November 18th & 19th · 2022

Organizing Committee:

Luis Paz-Ares
Rafael López
Elena Castro
Miguel Fernández de Sanmamed
Miguel Ángel Quintela
Jon Zugazagoitia

Scientific Committee:

Gabriel Capella	Francisco Real
Enrique de Álava	Cesar Serrano
Ignacio Durán	Marisol Soengas
David Olmos	Noelia Tarazona
Susana Puig	

Venue:

Hotel Los Abetos

Rúa de San Lázaro, s/n, 15820
Santiago de Compostela

Organized by:

aseica

FRIDAY, NOVEMBER 18TH

16:00-16:15 **WELCOME & INTRODUCTION**

16:15-16:45 **KEYNOTE LECTURE**
Thomas F. Gajewski

SESSION 1

16:45-16:55 **Introduction**

Chairpersons: Elena Castro, Josep Maria Piulats

16:55-17:02 **Advances and challenges in the fight against childhood cancer**
Antonio Pérez-Martínez

17:05-17:12 **Changes in the immune-system associated with prostate cancer progression**
Enrique Gonzalez Billalabeitia

17:15-17:22 **Combining radiotherapy and immunotherapy**
María Rodríguez-Ruiz

17:25-17:32 **Harnessing the tumour microenvironment to improve the efficacy of immunotherapy in head and neck carcinoma**
Antonio Rullán

17:35-17:42 **OVATIL: microenvironment characterization in ovarian cancer**
Aránzazu Manzano Fernández

17:45-17:52 **Humanized-PDX models to support the development of new cancer immunotherapies**
Miguel F. Sanmamed

17:55-18:25 **Discussion**

18:25-18:55 **COFFEE BREAK** ☕

FRIDAY, NOVEMBER 18TH

SESSION 2

- 18:55-19:05 **Introduction**
Chairpersons: Edurne Arriola, Miguel F. Sanmamed
- 19:05-19:12 **Immunotherapy for small cell lung cancer**
Antonio Calles
- 19:15-19:22 **Radon gas and lung cancer**
Laura Mezquita
- 19:25-19:32 **Research projects in lung cancer and mesothelioma**
Ernest Nadal
- 19:35-19:42 **Therapeutic targets in thoracic neoplasias**
Fernando López-Ríos
- 19:45-19:52 **Anti-tumor host immunity and response to chemo or chemoimmunotherapy in resectable NSCLC**
Pedro Rocha
- 19:55-20:02 **Identifying therapeutically amenable resistance mechanisms in the tumor microenvironment of human lung cancer**
Jon Zugazagoitia
- 20:05-20:35 **Discussion**
- 21:30 **DINNER 🍷🍷**

1st SIMPOSIO RETREAT

SATURDAY, NOVEMBER 19TH

SESSION 3

- 09:00-09:10 **Introduction**
Chairpersons: Gabriel Capella, Ignacio Durán
- 09:10-09:17 **Resistance mechanism in breast cancer HER2+**
Juan Miguel Cejalvo Andújar
- 09:20-09:27 **Drug resistance and DNA repair function in prostate cancer**
Joaquín Mateo
- 09:30-09:37 **Opportunities and challenges in precision medicine for rare tumors**
César Serrano García
- 09:40-09:47 **Biliary tract cancer: Last updates**
Angela Lamarca
- 09:50-09:57 **New treatments in IDH-mutant gliomas**
Juan Manuel Sepúlveda Sánchez
- 10:00-10:07 **Clinical implications of germline variants in prostate cancer**
Elena Castro
- 10:10-10:40 **Discussion**
- 10:40-11:20 **COFFEE BREAK** ☕

SATURDAY, NOVEMBER 19TH

SESSION 4

- 11:25-11:37 **Introduction**
Chairpersons: Rafael López, Noelia Tarazona
- 11:40-11:47 **The role of oxidative stress as a primary, or secondary, resistance mechanism to targeted cancer therapy**
Valentina Gambardella
- 11:50-11:57 **Castration resistance in metastatic prostate cancer patients: A biomarker study integrated within the multi-centre PRESIDE clinical trial**
María Ruiz Vico
- 12:00-12:07 **PARP inhibitors in gynecological tumors: resistance biomarkers**
Ainhoa Madariaga
- 12:10-12:17 **Precision imaging towards improving cancer treatment**
Raquel Pérez López
- 12:20-12:27 **Unveiling the role of endoplasmic reticulum stress responses in HCC**
Josep Maria Argemí
- 12:30-12:37 **New-omics in translational cancer research**
Miguel Ángel Quintela
- 12:40-13:10 **Discussion**
- 13:13-14:00 **Challenges and opportunities for physician-scientist career in Spain**
Luis Paz-Ares
Raquel Yotti
- VIRTUAL**
- 14:00-14:10 **CLOSING & FAREWELL**
Luis Paz-Ares
Marisol Soengas
- 14:10 **LUNCH** 🍴

1st SIMPOSIO RETREAT

PARTICIPANTS:

Josep Maria Argemí. Clínica Universidad de Navarra, Pamplona

Eurne Arriola. Hospital del Mar-Parc de Salut Mar, Barcelona

Antonio Calles. Hospital Gregorio Marañón, Madrid

Gabriel Capella. Institut d'Investigació Biomèdica de Bellvitge (IDIBELL), Barcelona

Elena Castro. Fundación del sector público estatal Centro Nacional de Investigaciones Oncológicas-CNIO, Málaga

Juan Miguel Cejalvo. Hospital Clínico Universitario de Valencia (INCLIVA), Valencia

Ignacio Durán. Hospital Universitario Marqués de Valdecilla- IDIVAL, Santander

Miguel F. de Sanmamed. Clínica Universidad de Navarra, Pamplona

Valentina Gambardella. Hospital Clínico de Valencia, INCLIVA

Thomas F. Gajewski. University of Chicago Medicine (USA)

Enrique González Billalabeitia. Hospital Universitario 12 de Octubre, Madrid

Ángela Lamarca. Hospital Universitario Fundación Jimenez Diaz, Madrid

Rafael López López. Complejo Hospitalario Universitario de Santiago, Santiago de Compostela

Fernando López-Ríos. Hospital Universitario 12 de Octubre, Madrid

Ainhoa Madariaga. Hospital Universitario 12 de Octubre, Madrid

Aránzazu Manzano. Hospital Clínico San Carlos, Madrid

Joaquín Mateo. Vall d'Hebron Institute of Oncology (VHIO), Barcelona

Laura Mezquita. Hospital Clínic, Barcelona

Ernest Nadal. Institut Català de Oncologia/IDIBELL - Hospital Duran i Reynals, Campus Bellvitge, Barcelona

Luis Paz-Ares. Hospital Universitario 12 de Octubre, Madrid

Raquel Pérez López. Vall d'Hebron Institute of Oncology (VHIO), Barcelona

Antonio Pérez-Martínez. Hospital Universitario La Paz, Madrid

Josep Maria Piulats. Institut Català de Oncologia (ICO), L'Hospitalet de Llobregat, Barcelona

Miguel Ángel Quintela. Programa de Investigación Clínica, Centro Nacional de Investigaciones Oncológicas (CNIO)

Pedro Rocha. Hospital del Mar, IMIM, Barcelona

María Rodríguez-Ruiz. Clínica Universidad de Navarra, Pamplona

María Ruiz Vico. Hospital Universitario 12 de Octubre, Madrid

Antonio Rullán. The Royal Marsden Hospital/The Institute of Cancer Research, London

Juan Manuel Sepúlveda. Hospital Universitario 12 de Octubre, Madrid

César Serrano García. Hospital Universitari Vall d'Hebron, Barcelona

Marisol Soengas. Centro Nacional de Investigaciones Oncológicas-CNIO, Madrid

Noelia Tarazona. Hospital Clínico Universitario de Valencia, Valencia

Raquel Yotti. Ministerio de Ciencia e Innovación, Madrid

Jon Zugazagoitia. Hospital Universitario 12 de Octubre, Madrid

1st SIMPOSIO RETREAT

GOLD SPONSORS



SILVER SPONSORS



BRONZE SPONSORS

AMGEN®

AstraZeneca 

 Bristol Myers Squibb™

Lilly

Pharma
Mar 

janssen  Oncology
PHARMACEUTICAL COMPANIES OF Johnson & Johnson





 GILEAD
Oncology

SECRETARÍA TÉCNICA:

 **tactics**

 Passatge Batlló 15, 08036 Barcelona

 93 451 17 24

 info@tacticsmd.net

 www.tacticsmd.net